Company: GANX
Filing Date: 2025-04-10
Form Type: 8-K
Source: 0001104659-25-033797
Chunk: 2

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-10
Form: 8-K
Item: Item 8.01
Chunk 2
---
 blood.
Biomarkers include GCase activity and protein levels, sphingolipid substrate levels, α-synuclein, lysosomal and mitochondrial markers,
and inflammatory markers. Results from this Phase 1b study will guide the design of a subsequent randomized, placebo-controlled, double-blind
dose-finding Phase 2 study to evaluate the efficacy of GT-02287 as measured by a clinically meaningful endpoint in PD over a longer treatment
period. Phase 2 planning is expected to commence in the second half of 2025.

Item 9.01 Financial Statements and Exhibits